<div id="readability-page-1"><p>Jump Financial LLC purchased a new position in  West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 20,239 shares of the medical instruments supplier's stock, valued at approximately $4,428,000.</p><ul><li>3 Dividend Champions with room for dividend growth</li></ul><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. SYM FINANCIAL Corp increased its position in  West Pharmaceutical Services by 5.1% in the second quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier's stock worth $225,000 after buying an additional 50 shares during the period.  Parkside Financial Bank &amp; Trust grew its position in shares of  West Pharmaceutical Services by 4.0% during the second quarter. Parkside Financial Bank &amp; Trust now owns 1,318 shares of the medical instruments supplier's stock worth $288,000 after acquiring an additional 51 shares during the last quarter.  MJP Associates Inc. ADV grew its position in shares of  West Pharmaceutical Services by 2.7% during the second quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier's stock worth $431,000 after acquiring an additional 52 shares during the last quarter.  Horizon Investments LLC increased its holdings in shares of  West Pharmaceutical Services by 5.8% in the 1st quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier's stock worth $234,000 after acquiring an additional 57 shares during the period.  Finally, Pallas Capital Advisors LLC lifted its position in  West Pharmaceutical Services by 1.0% in the 2nd quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier's stock valued at $1,386,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own  93.90% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research firms have commented on WST. Deutsche Bank Aktiengesellschaft  set a $345.00 target price on shares of West Pharmaceutical Services and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 24th. Wall Street Zen lowered West Pharmaceutical Services from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday. Rothschild &amp; Co Redburn assumed coverage on West Pharmaceutical Services in a research report on Monday, September 15th. They issued a &#34;buy&#34; rating and a $311.00 target price on the stock. UBS Group boosted their price target on West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 24th. Finally, Cowen started coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They issued a &#34;buy&#34; rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned  a Hold rating to the company. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $343.36.</p><ul><li>What Factors Will Drive S&amp;P 500 Performance This Year?</li></ul><p><b>View Our Latest Stock Report on West Pharmaceutical Services</b></p><h2>West Pharmaceutical Services Stock Performance</h2><p>WST opened at $266.02 on Wednesday. The company has a market capitalization of $19.14 billion, a price-to-earnings ratio of 39.41, a price-to-earnings-growth ratio of 4.16 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $348.90. The business has a 50 day moving average price of $273.94 and a two-hundred day moving average price of $249.16. </p><ul><li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li></ul><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.29. The company had revenue of $804.60 million for the quarter, compared to analysts' expectations of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS.  Research analysts predict that  West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year. </p><h2>West Pharmaceutical Services Profile</h2> (Free Report)<p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than West Pharmaceutical Services</li><li>What is diluted earnings per share (Diluted EPS)?</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>Stock Analyst Ratings and Canadian Analyst Ratings</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li></ul><p><strong>Want to see what other hedge funds are holding WST?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p><p>While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Jump Financial LLC invested $4.43 million in West Pharmaceutical Services, Inc. during Q2, purchasing 20,239 shares. Other institutional investors also adjusted their positions. Analysts have mixed ratings, with a consensus of "Moderate Buy" and a target price of $343.36. West Pharmaceutical Services reported Q3 earnings of $1.96 per share, beating estimates, with revenue up 7.7% year-over-year. The company has a market cap of $19.14 billion and a 1-year stock range of $187.43-$348.90.</p>

Jump Financial LLC Invests $4.43 Million in West Pharmaceutical Services, Inc. $WST